|Over a week ago|
Mersana Therapeutics to host conference call » 16:2503/3003/30/20
Conference call to…
Mersana Therapeutics updates data from XMT-1536 Phase 1 dose escalation study » 16:0703/3003/30/20
Mersana Therapeutics announced updated efficacy and safety data in patients with ovarian cancer and non-small cell lung cancer, NSCLC, adenocarcinoma from its ongoing Phase 1 dose escalation study evaluating XMT-1536. The Company will host a call, Monday, March 30, at 5:00 pm ET during which investigator Debra L. Richardson, MD, Associate Professor of Gynecologic Oncology at the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center and the Sarah Cannon Research Institute and members of the Mersana executive team will present and discuss these data. "These data demonstrate that XMT-1536, our first-in-class Dolaflexin ADC targeting NaPi2b, delivers confirmed responses and durable stable disease in heavily pretreated ovarian cancer and NSCLC adenocarcinoma patients who have exhausted all other treatment options. These data also show that XMT-1536 is well tolerated without the severe toxicities of other ADC platforms such as neutropenia, neuropathy and ocular toxicity. Moreover, these data establish the potential for a biomarker-response relationship to identify patients most likely to benefit from XMT-1536," said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. "We look forward to advancing XMT-1536 for both ovarian cancer and NSCLC adenocarcinoma patients. Having already accumulated meaningful patient experience in the expansion cohorts, we remain on track to provide an interim update in the second quarter of 2020." Of the 59 patients enrolled, tumor types included 37 ovarian cancer, 11 NSCLC adenocarcinoma, and 11 other tumor types previously disclosed at lower dose levels. Patients were heavily pre-treated, with a median of five prior lines of treatment (range 1-10). These data include new patients dosed at 30, 36 and 43 mg/m2. The majority of the ovarian cancer patients had received prior bevacizumab or PARP inhibitors. All NSCLC adenocarcinoma patients had received prior platinum and immunotherapy.
Mersana Therapeutics to host conference call » 04:5503/3003/30/20
Conference call to…
Mersana Therapeutics to host conference call » 17:2803/2203/22/20
Conference call to…
Mersana Therapeutics to present updated data from the XMT-1536 Phase 1 study » 08:0903/2003/20/20
Mersana Therapeutics reaffirmed previously announced plans to host a live conference call and webcast on Monday, March 30, 2020 at 5:00 p.m. ET to report updated data from the ongoing XMT-1536 Phase 1 dose escalation study. Members of the Mersana executive team will be joined by investigator, Debra L. Richardson, MD, Associate Professor of Gynecologic Oncology at the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center and the Sarah Cannon Research Institute in Nashville, TN. Mersana Therapeutics had previously announced plans to present the updated XMT-1536 Phase 1 dose escalation data in a late-breaking oral presentation at the now cancelled Society of Gynecologic Oncology 2020 Annual Meeting on Women's Cancer in Toronto, Canada.
|Over a month ago|
Mersana Therapeutics reports Q4 EPS (34c), consensus (38c) » 06:0402/2802/28/20
Cash, cash equivalents…
Cash, cash equivalents and marketable securities as of December 31, 2019, were $99.8M, compared to $70.1M as of December 31, 2018. In addition, the Company has the option to draw additional funds of up to $15M through the existing debt financing agreement with Silicon Valley Bank. The company expects that its current cash, cash equivalents and marketable securities will enable it to fund its operating plan through important milestones, including the XMT-1536 Phase 1 clinical study and the planned dose escalation study for XMT-1592.
Four new option listings and one option delisting on February 12th » 08:3002/1202/12/20
MRSN, PPD, QMCO, YMAB, CRCM
New option listings for…
New option listings for February 12th include Mersana Therapeutics (MRSN), PPD Inc (PPD), Quantum Corporation (QMCO), and Y mAbs Therapeutics Inc (YMAB). Option delistings effective February 12th include Care com Inc (CRCM).
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright » 07:2301/2101/21/20
H.C. Wainwright analyst…
H.C. Wainwright analyst Debjit Chattopadhyay raised Mersana Therapeutics' price target to $12 from $7 and reiterates a But rating on the shares. Safety of the dolaflexin platform is being increasingly validated with the 43 mg/m dose moving to the expansion cohort, Chattopadhyay tells investors in a research note.
Mersana says Immunosynthen platform on track for development candidate in 2020 » 08:1301/1001/10/20
Immunosynthen platform on…
Immunosynthen platform on track to deliver a STING agonist ADC development candidate in 2020. The Company has developed a novel STING agonist ADC platform and has generated preclinical data across multiple targets and models showing complete regression of tumors in vivo with a single, well-tolerated dose, consistent with increased cytokine expression and immune cell infiltration within the tumor. The Company expects to finalize the platform design and target evaluation and select its first STING agonist ADC development candidate in the second half of 2020. The Company also expects to disclose additional preclinical data at scientific meetings throughout 2020.
Mersana Therapeutics expects to disclose development candidate in 2H20 » 08:1201/1001/10/20
Initiating IND-enabling studies of a first-in-class B7-H4 ADC candidate. B7-H4 is expressed on both tumor cells and tumor-associated macrophages. A B7-H4 ADC delivering a DolaLock payload has been shown in preclinical studies to exert a direct cytotoxic effect via uptake by tumor cells, as well as deliver additional payload release in the tumor environment through binding and catabolism in B7-H4-expressing TAMs. It has been shown that the DolaLock payload can activate dendritic cells and induce immunogenic cell death, with the potential to provide a secondary, immune-based anti-tumor effect in addition to the primary cytotoxic effect. The Company expects to disclose its development candidate and supporting data in the second half of 2020.